Sicca syndrome following immune checkpoint inhibition.

Sicca syndrome following immune checkpoint inhibition. Clin Immunol. 2020 Jun 09;:108497 Authors: Mavragani CP, Moutsopoulos HM Abstract The recent approval of Immunologic checkpoint inhibitors as an effective therapeutic strategy against cancer came at the cost of toxicities mediated by an excessive activation of immune system against health tissues, including among others musculoskeletal and sicca complaints.The latter occur in the context of an entity reminiscent of Sjogren's syndrome, with distinct characteristics such as abrupt onset, male predominance, lower prevalence of autoantibodies and response to steroids. PMID: 32531346 [PubMed - as supplied by publisher]
Source: Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Clin Immunol Source Type: research